https://www.selleckchem.com/pr....oducts/tideglusib.ht
9±10.2%, which was significantly superior compared with those with MYCN-nonamplified high-risk neuroblastoma (16.7±8.8%; p.001). MYCN amplification was the most favorable prognostic factor for EFS (hazard ratio=0.29; 95% confidence interval=0.12-0.66). Of the 41 patients, three died because of regimen-related toxicity (infection, n=2; microangiopathy, n=1). The thiotepa-melphalan high-dose therapy with thiotepa and melphalan may be effective for high-risk neuroblastoma. However, this regimen is toxic and warrants special attentio
Like
Comment
Share
